harmacological termination by class I antiarrhythmic drugs (AADs) is usually considered an effective treatment for atrial fibrillation (AF), 1 but restoration and maintenance of sinus rhythm (SR) can be difficult in patients with long-lasting AF. Furthermore, even if SR is restored by pharmacological conversion with class I AADs, AF recurs in more than 50% of patients during the followup period. [2] [3] [4] [5] [6] [7] [8] Bepridil is a unique AAD with a calcium-channel blocking effect, but is also known to have sodium-and potassiumchannel blocking actions. [9] [10] [11] [12] In particular, its potassiumchannel blocking action is relatively strong, and therefore bepridil is expected to be quite effective in the management of AF, similar to amiodarone. [13] [14] [15] In fact, several studies have demonstrated the efficacy and safety of bepridil or combination therapy using bepridil with aprindine for converting AF to SR. [14] [15] [16] [17] However, few studies have attempted to determine the efficacy and safety of combined therapy with bepridil and other AADs. Furthermore, despite the clinical efficacy of bepridil, previous reports have emphasized the risk of torsades de pointes (TdP) because of QT prolongation related to its relatively strong potassiumchannel blocking action. 18, 19 We examined for the first time the efficacy and safety of additional treatment with bepridil in patients with AF who had been treated with class I AADs.
Methods

Study Population
This study included 76 consecutive patients with class I AAD-resistant AF (53 males, 23 females; mean age, 60.8± 10.8 years; range, 31-84 years; Table 1 ). Forty-nine patients had drug-resistant, symptomatic paroxysmal AF, and the remaining 27 had persistent AF, which was defined as a non-self-terminating AF lasting at least 1 month. The mean duration of the AF history was 5.2±5.6 years (range, 2 months to 30 years) in all and the mean duration of persistent AF was 7.5±8.0 months (range, 1-28 months) in the 27 patients with persistent AF (Table 1) . At the time of enrollment in this study, all patients had been treated with 1 or more of the class I AADs (Table 1) . Paroxysmal AF was treated with at least 2 class I AADs in 38 patients. In the remaining 11 patients, of whom 8 had sick sinus syndrome, 2 had mitral valvular disease, and 1 had congenital heart disease, only 1 class I AAD was tested because of the difficulty of carrying out numerous trials of class I AADs and/or patient's intolerance to other AADs. A mean of 1.9± 0.9 AADs (range, [1] [2] [3] [4] [5] were ineffective in preventing recurrences of AF or restorating SR (Table 1) . In all patients, AF was considered to be drug resistant for the following reasons: symptomatic episodes of the AF attacks were not controlled (or the number of AF attacks did not decrease) Thirteen patients had hypertension, 9 had sick sinus syndrome, 4 had mitral valvular diseases, 2 had hypertrophic cardiomyopathy, 2 had congenital heart diseases, 1 had ischemic heart disease, and the remaining 45 patients (59%) had no structural heart disease ( Table 1) . Echocardiography demonstrated a mean left ventricular ejection fraction (LVEF) of 64±8% (range, 52-80%), and mean left atrial diameter (LAD) of 41.1±6.6 mm (range, 34-58 mm). In 19 (25%) patients, the LAD was larger than 45 mm.
The exclusion criteria were: (1) LVEF <40%, or history of congestive heart failure, (2) myocardial infarction or revascularization within past 3 months, (3) simultaneous treatment with radiofrequency catheter ablation, and (4) corrected QT (QTc) interval (QTc) >500 ms on baseline ECG.
Study Protocol
After informed consent was given, 50-200 mg/day (mean dosage, 134±44 mg/day) of oral bepridil was added to the treatment with a class I AAD that the patient had been receiving, after consideration of the patient's age, gender, renal function, body weight, and the dosage of the class I AAD. To avoid TdP and other complications, the initial dose of bepridil was small to moderate, usually 50-150 mg/day for 2-4 weeks, but was increased up to 200 mg/day when the initial dose was ineffective in suppressing the AF or in restoring SR under careful observation using periodic ECG recordings and assessing general status. As antithrombotic therapy, aspirin (100 mg/day) or warfarin was administered to all patients. The dose of the warfarin was set to an international normalized ratio between 1.6 and 3.0. Periodic blood tests were also performed. If the treatment was determined to be effective, the dosage of bepridil was maintained unless obvious adverse complications were noted. If the QT interval was prolonged (>500 ms) within 1 month after starting treatment with bepridil, it was discontinued or the dose was decreased. In patients with persistent AF in whom SR was not restored within 1 month after administration of oral bepridil in addition to a class I AAD, transthoracic electrical cardioversion was performed. Four of 9 patients who had sick sinus syndrome were implanted with a pacemaker during bepridil treatment because of severe symptoms associated with sinus pauses.
All patients were followed up once or twice every month at the outpatient clinic of the Gunma Prefectural Cardiovascular Center. The patient's symptoms and ECG findings, whether or not SR was maintained without any AF recur- episodes of AF in the patients with paroxysmal AF or when restoration and maintenance of SR was achieved in the patients with persistent AF. 20 The patients were divided into 2 groups based on these criteria from the results of AF status at the end of a mean follow-up period of 27±22 months (range, 10 months to 10.5 years): bepridil effective group (Bep-effect (+) group) and ineffective group (Bepeffect (-) group).
ECG Analysis and Other Measurement Variables
The ECG parameters, including heart rate, QT and QTc intervals were measured before and after bepridil administration. The ECG was recorded at a paper speed of 25 mm/s. The QT intervals that spanned the onset of the QRS complex to the end of the T wave were determined from the lead with the longest QT interval 21 and the same lead was used for serial measurements in each patient. The point at which the tangent drawn to the steepest portion of the downsloping T wave intersected the isoelectric line was used as the end of the T wave.
In the present study, we also examined (1) the incidence of restoring and maintaining SR in patients with persistent AF, (2) AF occurrence in patients with paroxysmal AF, (3) changes in the ECG parameters before and after bepridil treatment, and (4) incidence of complications.
Statistical Analysis
All variables are expressed as the mean ± SD, and were compared using Student's t-test. Categorical variables were compared using chi-squared analysis and Yate's correction if necessary. An overall chi-squared test for a 2×n table was constructed when comparisons involved >2 groups. A p-value <0.05 was considered statistically significant.
Results
Effect of Additional Treatment With Bepridil on Symptomatic AF Episodes in Patients With Paroxysmal AF
After the addition of bepridil to the class I AAD, the frequency of symptomatic episodes of AF decreased to less than 10% in 38 (78%) of 49 patients with paroxysmal AF (Table 2 ). In patients with paroxysmal AF, the daily dosage of oral bepridil was 120±34 mg in the Bep-effect (+) group and 121±49 mg in the Bep-effect (-) group (p=0.22). There was no significant difference in the demographics or clinical data (age, gender, type of AF, prevalence of structural heart disease, duration of AF, or total number of class I AADs used before the study), frequency of use of other drugs (angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers, -blockers, or statins), LVEF, or LAD between the 2 groups (Table 2) . However, the QTc interval was longer in the Bep-effect (+) group than in the Bepeffect (-) group before bepridil treatment (p=0.06), and that difference was significant after bepridil treatment (p<0.05; Table 2 ).
The detailed daily dosages of bepridil and the class I AADs and the efficacy of the combined treatment for each dosage are shown in Table 3 . With the combination of a moderate dose (50-150 mg/day) of bepridil and each dosage of the class I AADs, therapy was effective in 35 (83%) of 42 patients, but was effective in 3 (43%) of 7 patients to whom a large dose of bepridil (200 mg/day) was given (p=0.059; Table 3 ).
Effect of Additional Treatment With Bepridil on the Restoration and Maintenance of SR in Patients With Persistent AF
After the addition of bepridil to the class I AADs, SR was restored in 14 (50%) of 27 patients with persistent AF 1.2±1.1 months (range; 0.3-3.2 months) after treatment with bepridil. In 10 of 13 patients in whom SR could not be restored within 1 month after administration of bepridil, transthoracic electrical cardioversion was performed, and SR was restored in 6 patients. In those 20 (74%) patients in whom SR was restored, it was maintained without AF recurrence during a mean follow-up period of 25±22 months (range, 10-125; Bep-effect (+) group; Table 4 ). However, SR was not restored or maintained in the remaining 7 (26%) patients (Bep-effect (-) group). In the patients with persistent AF, the daily dosage of oral bepridil was 137± 33 mg in the Bep-effect (+) group and 156±50 mg in the Bep-effect (-) group (p=0.64). Although no significant difference was found in the demographic and clinical data, LVEF or ECG findings before or after bepridil treatment (heart rate and QTc interval) between the 2 groups, the LAD was smaller in the Bep-effect (+) group than in the Bep-effect (-) group (p<0.05; Table 4 ). The detailed daily dosage of bepridil and the class I AADs, and the efficacy of the combined treatment for each dosage are shown in Table 5 . With the combination of a moderate dose (50-150 mg/day) of bepridil and each dosage of the class I AADs, therapy was effective in 17 (81%) of 21 patients, but was effective in 3 patients (50%) to whom a large dose of bepridil (200 mg/day) was given (p=0.32; Table 5 ).
Efficacy of Additional Treatment With Bepridil in All Patients With AF
Overall, combined therapy using oral bepridil and a class I AAD was effective in 58 (76%) patients (Bep-effect (+) group) and ineffective in the remaining 18 (24%) patients (Bep-effect (-) group; Table 6 ). The therapy was effective in 12 (63%) of 19 patients with a large LA (LAD >45 mm). However, no significant difference was found between the 2 groups in the daily dosage of oral bepridil (p=0.27; Table 6 ), demographic and clinical data, type of class I AAD given to the patient with bepridil, or the frequency of using other drugs (Table 7) , and the LAD was smaller in the Bep-effect (+) group than in the Bep-effect (-) group (p<0.05; Table 7 ).
ECG Parameters Before and After Additional Administration of the Bepridil With Class I AADs in Patients With Paroxysmal and Persistent AF and the Complications
With the addition of bepridil to the class I AADs, the heart rate decreased slightly from 74.9±20.5 to 71.9± 17.5 beats/min (p=0.36; Table 1 ). However, the QTc interval was prolonged from 441±40 ms to 475±40 ms (p<0.05; Table 1 ). Although no patient had marked prolongation of the QT interval (>600 ms) or developed TdP, moderate prolongation of the QT interval (>500 ms) was found in 15 (20%) patients after addition of bepridil to the class I AADs: 2 patients discontinued bepridil because it was ineffective, and the remaining 13 continued with a reduced daily dosage because it was effective. No other adverse effects, including liver injury, necessitating drug discontinuation, occurred during the follow-up period.
Discussion
Major Findings
The results of this study demonstrate that the additional administration of bepridil with class I AADs that have been used as treatment, but have been ineffective in treating AF, was effective in 78% of patients with paroxysmal AF and in 74% of the patients with persistent AF. The efficacy of this combined therapy for AF was usually obtained with small to moderate dosages (50-150 mg/day) of bepridil, and decreased with large dosages (200 mg/day). Although a reduction in the daily dose of bepridil was required in selected patients because of marked prolongation of the QT interval, no potential complications occurred during the follow-up period. These results indicate that, in patients who are resistant to class I AADs, the addition of bepridil may be effective in suppressing AF attacks and restoring and maintaining SR.
Proposed Mechanism of the Combined Therapy of Class I AADs and Bepridil for Paroxysmal and Persistent AF
In general, class I AADs are believed to interrupt reentrant arrhythmias by causing conduction block in the critical part of the re-entrant circuit, whereas class III drugs cause interruption by prolonging refractoriness. 22, 23 Class I AADs are widely used as a treatment for suppressing attacks of AF in patients with paroxysmal AF and for restoring and maintaining SR in patients with persistent AF. 1 Their efficacy for AF is superior to a placebo, but is modest and a considerable number of AF patients are resistant to class I AADs. [2] [3] [4] [5] [6] [7] [8] Bepridil is classified as a class IV AAD, but it is a multichannel blocker inhibiting both L-and T-type calcium channels, sodium channels and several potassium channels, including the ultra-rapid (Ik-ur), rapid (Ikr) and slow components of the delayed rectifier potassium channels. [9] [10] [11] [12] [13] Recently, bepridil gained much attention because of its remarkable ability to suppress AF episodes in paroxysmal AF 14, 15 and to terminate persistent or chronic AF. 16, 17 In a comparison of the effects of amiodarone and bepridil in patients with chronic AF, bepridil was reported to be more effective than amiodarone. 18 The Ik-ur, which exists only in the atrium, is specifically blocked by bepridil, but not by amiodarone, 24 and the combined inhibition of the Ikr and Ik-ur by bepridil is synergistic and produces a greater prolongation of the action potential duration (APD) than the sum of the effects of individual channel blockades. 25 The superior efficacy of bepridil over amiodarone may be explained by the Ik-ur blocking effect.
One of the important components of AF-related remodeling is the downregulation of the L-type calcium channels, which reduces the effective refractory period (ERP). 26 Amiodarone preserves the downregulation of L-type calcium channels and the blocking effects of the T-type calcium channels, and reserves the shortening of the ERP. 27 Bepridil inhibits T-type calcium channels, as well as L-type calcium channels, similarly to amiodarone, and may reverse some remodeled channels. 26 In the present study, the addition of bepridil to the class I AAD therapy was effective in 78% of the patients with paroxysmal AF and 74% of the patients with persistent AF who had been resistant to treatment with class I AADs. A recent study showed that bepridil suppressed ERP shortening and tended to prolong it, but did not affect the conduction velocity opposing the blocking effects of the sodium channels, so its suppressive effect on AF-related remodeling might be considered as partial. 28 Although the precise mechanism of the effectiveness of the combined treatment for paroxysmal and persistent AF was not clarified in the present study, bepridil would enhance the sodium-channel blocking effect of class I AADs because bepridil prolongs both the APD and the duration of the inactivated state of the sodium channel in the atrium, and it may increase the ERP, thereby contributing to conduction delay at pivotal points of functional reentry, organization of the fibrillation wave, and prolongation of the fibrillation cycle length. These effects have an increased possibility of eliminating all circulating wavelets simultaneously.
Previous Studies
The effect of bepridil and of combined treatment with bepridil and aprindine on paroxysmal AF and persistent AF has been reported. 16, 17 Nakazato et al reported that in 70 of 112 (81%) patients with persistent AF SR was maintained by bepridil alone. 17 Fujiki et al reported that in 11 of 16 (69%) patients with persistent AF SR was maintained by the combination of aprindine and bepridil. 16 However, no study has ever attempted to clarify the utility and safety of additional treatment with bepridil with class I AADs other than aprindine. In the present study, we demonstrate for the first time that the administration of bepridil to class I AADs that have been ineffective in treating the AF was effective in 78% of the patients with paroxysmal AF and 74% of the patients with persistent AF.
The effect of other AADs on paroxysmal AF and persistent AF has also been reported. 29, 30 Roy et al demonstrated that AF recurred in 71 of 201 (35%) patients using amiodarone and in 127 of 201 (63%) patients using sotalol or propafenone during a mean follow-up period of 16 months. 29 Komatsu et al demonstrated that amiodarone maintained SR at 12 months in 30 of 55 (55%) patients with drug-resistant AF. 30 In the present study, SR was maintained in all patients who had SR restored during a mean follow-up of 25 months, which was superior to that of amiodarone or sotalol.
Clinical Implications and Adverse Complications
From the results of our study, when a class I AAD is ineffective for suppressing AF episodes in patients with paroxysmal AF or can not restore SR in patients with persistent AF, bepridil should be added to the drug regimen.
Despite the efficacy of bepridil on AF, the relatively strong potassium-channel blocking effect contributes to a marked prolongation of the QT interval and to a possible risk of TdP. 18, 19 Perelman et al reported that oral bepridil (200-600 mg/day) was associated with the development of serious ventricular arrhythmias because of excessive prolongation of the QT interval. 18 In the present study, however, the maximum dosage of bepridil was 200 mg/day and careful follow up including observation of the QT interval was performed to avoid its pro-arrhythmic effects. This dosage resulted in no serious complications, except for 2 cases of QT prolongation in which we ceased bepridil administration. A recent study reported that adverse effects were observed in 19 patients (4%) during an average follow-up of 20 months (marked QT prolongation >550 ms in 13 patients, bradycardia ≤40 beats/min in 6 patients, dizziness and general fatigue in 1 patient each), and that hypokalemia and a sudden decrease in the heart rate are the major triggering factors of TdP. 19 Although none of those adverse effects, except for prolongation of the QT interval (>500 m), occurred in the present study, we should always bear in mind the risk of TdP, and much attention should be paid to periodic ECG recordings and the general status of the patient during follow-up.
Study Limitations
First, because we did not examine the effect of bepridil alone on drug-resistant AF, whether or not the patients who responded to the combined therapy may also have responded to bepridil alone remains unclear. Furthermore, bepridil was administered to AF patients who did not respond to any of the class I AADs, and then, several class I AADs were tested. Fortunately, we demonstrated the efficacy and safety of the combined therapy of bepridil and a class I AAD on drug-resistant AF in the present study, although we could not clarify the precise mechanism of action.
Second, this study was a retrospective and non-randomized study without any controls performed in a single center and included several different class I AADs. Furthermore, our sample size was small and the follow-up period was relatively short. Therefore, sampling bias could not be eliminated. Further studies with a larger number of patients, designed prospectively using a few class I AADs and a longer follow-up period may be needed to confirm and extend our results.
Third, as mentioned above, because of the variety of class I AADs, and because the number of patients using each AAD was small, we could not clarify the differences between patients who responded to class I AADs and those who did not. Previous studies have shown that class I AADs are not sufficient in many patients with long-lasting AF and a large LAD. [2] [3] [4] [5] [6] [7] [8] In this study, the AF duration and LAD were comparable with those in the previous studies.
Fourth, we checked the recurrence of AF by symptoms, periodic 12-lead ECGs, and 24-h Holter monitoring. However, there is the possibility that a negative chronotropic effect of bepridil might have obscured the severity of patient symptoms during AF attacks. Furthermore, Page et al reported that in patients with PAF, sustained asymptomatic AF occurred more frequently than symptomatic AF. 31 Therefore, the frequency of AF episodes may have been underestimated in the present study.
Conclusions
The addition of bepridil to therapy with a class I AAD is effective in paroxysmal and persistent AF patients who are resistant to the class I AAD alone. Under careful observation of the general status of the patient and periodic ECG recordings, a satisfactory outcome was obtained without any potential complications in 78% of patients with paroxysmal AF and 74% of patients with persistent AF who were resistant to class I AADs alone.
